跳至主要内容
临床试验/DRKS00033697
DRKS00033697已完成Unknown

Clinical performance evaluation of three continuous glucose monitoring systems in adults with diabetes mellitus using a newly proposed testing procedure - IfDT-2332-I

Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm (IfDT)0 个研究点目标入组 24 人开始时间: 2024年3月26日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Clinical diagnosis of type 1 or type 2 diabetes mellitus
  • 2. Age = 18 years
  • 3. Intensive insulin therapy established for at least six months
  • 4. An understanding of and willingness to follow the protocol
  • 5. Signed informed consent

排除标准

  • 1. HbA1c > 10%
  • 2. Hypoglycemia unawareness
  • 3. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment
  • 4. Severe acute or severe chronic illness (at the physician’s discretion)
  • 5. Known severe skin reactions (including allergic contact dermatitis) or allergies to medical adhesives
  • 6. Skin alteration at the insertion sites (e.g., severe psoriasis vulgaris, severe scaring, severe lipodystrophia, severe rash)
  • 7. Female subjects: pregnancy, lactation period, lack of a negative pregnancy test (except in case of reported menopause, sterilization or hysterectomy)
  • 8. Any incapacity or general condition that, in the opinion of the investigator, prevents adequate compliance with the study procedures, e.g., mental or visual incapacity, language barriers, alcohol or drug misuse
  • 9. Dependency from the sponsor or the clinical investigator
  • 10. Intake of substances known to affect the performance of the investigational CGM systems, i.e., hydroxyurea, acetaminophen, and nutritional supplementation of ascorbic acid (vitamin C)
  • 11. Planned medical procedures during the core study period that could affect the performance of the investigational CGM systems, including magnetic resonance imaging, computer tomography scan, radiofrequency ablation, high-frequency electrical heat or high intensity focused ultrasound
  • 12. Infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immuno-deficiency virus (HIV) or other chronic infectious disease
  • 13. Body mass index (BMI) <20 kg/m²
  • 14. Intake of anticoagulants, except for acetylsalicylic acid in doses up to 100 mg

研究者

发起方
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm (IfDT)

相似试验